Increlex Mecasermin: Complete Medication Information Guide for Severe IGF-1 Deficiency Treatment

Introduction to Increlex (Mecasermin)

Increlex is a prescription injectable medication containing mecasermin, a recombinant form of human insulin-like growth factor-1 (IGF-1). It is designed for specific pediatric patients who have severe primary IGF-1 deficiency, a rare condition associated with impaired growth caused by insufficient IGF-1 activity in the body.

IGF-1 is a naturally occurring hormone that plays an important role in normal childhood growth and development. In individuals with severe primary IGF-1 deficiency, the body may not produce enough functional IGF-1 despite normal or elevated growth hormone levels.

Increlex provides recombinant IGF-1 to help address this specific deficiency under medical supervision. It is prescribed by specialists who evaluate growth patterns, laboratory results, medical history, and overall health status before initiating treatment.

What Is Increlex (Mecasermin)?

Increlex contains mecasermin, which is a recombinant human insulin-like growth factor-1 (rhIGF-1).

The medication belongs to a class of biological therapies designed to replace or supplement IGF-1 activity in patients who have severe deficiency.

Increlex is administered through subcutaneous injection, meaning the medication is injected under the skin according to healthcare provider instructions.

The medication is primarily used for:

• Severe primary IGF-1 deficiency (SPIGFD)
• Growth failure associated with specific IGF-1-related disorders
• Certain cases involving growth hormone gene deletion with neutralizing antibodies to growth hormone

Understanding IGF-1 and Its Role in Growth

Insulin-like growth factor-1 (IGF-1) is a hormone involved in childhood growth and development.

IGF-1 contributes to:

• Bone growth
• Muscle development
• Cell growth regulation
• Tissue development
• Normal physical maturation

The body normally produces IGF-1 mainly through stimulation by growth hormone.

In severe primary IGF-1 deficiency, the body’s ability to produce or respond appropriately to IGF-1 is impaired. This may result in significant growth limitations.

How Increlex Works

Increlex works by providing recombinant IGF-1 to patients whose bodies have insufficient IGF-1 activity.

Unlike growth hormone therapy, which stimulates the body to produce IGF-1, Increlex directly supplies recombinant IGF-1.

This distinction is important because some individuals with severe primary IGF-1 deficiency may not respond adequately to growth hormone due to problems within the growth hormone–IGF-1 pathway.

Healthcare providers determine whether direct IGF-1 replacement is appropriate based on diagnostic testing and clinical evaluation.

Medical Uses of Increlex

Severe Primary IGF-1 Deficiency

Increlex is approved for treating growth failure in children aged 2 years and older with severe primary IGF-1 deficiency.

This condition is typically identified through evaluation of:

• Growth patterns
• Height measurements
• IGF-1 laboratory levels
• Growth hormone status
• Medical history

Growth Hormone Gene Deletion With Neutralizing Antibodies

Increlex may also be used in children with growth hormone gene deletion who have developed neutralizing antibodies against growth hormone.

Conditions Increlex Is Not Intended For

Increlex is not approved for general height enhancement or routine short stature without confirmed severe primary IGF-1 deficiency.

It is also not intended as a replacement for growth hormone therapy in approved growth hormone deficiency conditions.

Healthcare professionals determine appropriate treatment based on diagnosis rather than height alone.

Benefits of Increlex Treatment

When prescribed for appropriate patients, Increlex may provide therapeutic benefits related to IGF-1 replacement.

Potential benefits may include:

Supporting Growth in IGF-1 Deficiency

By supplying recombinant IGF-1, Increlex may help address the underlying hormone deficiency responsible for impaired growth.

Targeted Hormone Replacement

Increlex provides a targeted approach for patients whose primary issue involves insufficient IGF-1 activity.

Specialist-Guided Treatment

Treatment involves ongoing monitoring by healthcare professionals experienced in pediatric growth disorders.

Monitoring may include:

• Growth progression
• IGF-1 levels
• Treatment response
• Blood glucose levels
• Potential adverse effects

Important Safety Information About Increlex

Because IGF-1 affects multiple biological processes, Increlex requires careful medical supervision.

Healthcare providers consider important safety factors before and during treatment.

Hypoglycemia Risk

IGF-1 may affect blood glucose regulation. Low blood sugar (hypoglycemia) is an important safety consideration associated with mecasermin therapy.

Patients and caregivers may receive guidance on recognizing symptoms such as:

• Dizziness
• Shakiness
• Sweating
• Hunger
• Confusion
• Weakness

Allergic Reactions

Serious allergic reactions, including anaphylaxis, have been reported with Increlex. Patients should seek immediate medical attention if symptoms of severe allergic reaction occur.

Increased Intracranial Pressure

Healthcare providers monitor for symptoms associated with increased pressure inside the skull, which may include:

• Headache
• Visual changes
• Nausea
• Vomiting

Possible Side Effects of Increlex

Like other prescription medications, Increlex may cause side effects.

Possible side effects may include:

• Hypoglycemia
• Injection site reactions
• Headache
• Joint pain
• Enlarged tonsils
• Ear infections
• Muscle or tissue discomfort

The healthcare provider should be informed about persistent or concerning symptoms.

Serious adverse reactions require immediate medical evaluation.

Increlex Drug Interactions and Treatment Considerations

Patients and caregivers should provide healthcare providers with complete medical information, including:

• Current medications
• Medical conditions
• Allergies
• Previous hormone treatments
• Other supplements

Healthcare providers evaluate potential interactions and determine appropriate monitoring requirements.

Proper Use of Increlex

Increlex should be administered exactly as prescribed.

Important treatment principles include:

• Follow injection instructions provided by healthcare professionals
• Use the prescribed dose only
• Maintain scheduled medical appointments
• Monitor for side effects
• Store medication according to manufacturer instructions

Dose adjustments should only be made by the prescribing healthcare provider.

Who May Receive Increlex Treatment?

Increlex is intended for specific pediatric patients who meet diagnostic criteria for severe primary IGF-1 deficiency.

Healthcare specialists evaluate:

• Age
• Growth history
• Laboratory findings
• IGF-1 levels
• Growth hormone status
• Overall medical condition

A confirmed diagnosis is required before treatment decisions are made.

Increlex and Healthcare Provider Monitoring

Long-term monitoring is an essential part of Increlex therapy.

Healthcare providers may monitor:

• Height and growth velocity
• Weight changes
• IGF-1 response
• Blood glucose levels
• Injection site reactions
• Overall treatment safety

Regular follow-up helps ensure treatment remains appropriate and effective.

Frequently Asked Questions About Increlex (Mecasermin)

What is Increlex?

Increlex mecasermin is a prescription medication containing mecasermin, a recombinant human IGF-1 used for treating severe primary IGF-1 deficiency-related growth failure.

What is mecasermin used for?

Increlex mecasermin is used to treat growth failure in children with severe primary IGF-1 deficiency or specific growth hormone-related conditions involving neutralizing antibodies.

Is Increlex the same as growth hormone?

No. Increlex mecasermin provides recombinant IGF-1 directly, while growth hormone stimulates the body’s production of IGF-1.

How is Increlex administered?

Increlex mecasermin is administered by subcutaneous injection according to healthcare provider instructions.

Who should prescribe Increlex?

Increlex mecasermin should be prescribed and monitored by qualified healthcare professionals experienced in managing pediatric growth disorders.

Can Increlex increase height in anyone?

No. Increlex mecasermin is specifically indicated for children with severe primary IGF-1 deficiency and is not a general height enhancement medication.

Increlex mecasermin is a prescription medication containing recombinant human insulin-like growth factor-1 (IGF-1). It is indicated for the treatment of growth failure in pediatric patients aged 2 years and older with severe primary IGF-1 deficiency or growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

Mecasermin works by providing IGF-1, an important hormone involved in childhood growth and development. Increlex is administered by subcutaneous injection and is intended for use under the supervision of a qualified healthcare professional. Increlex mecasermin

Because Increlex can produce significant effects on blood glucose, hypoglycemia is an important safety consideration. Other potential risks include allergic or hypersensitivity reactions and other complications requiring medical monitoring. Increlex mecasermin

Important: Increlex (mecasermin) is a prescription medication intended for specific pediatric growth disorders. It should only be used under appropriate medical supervision and is not a general-purpose growth or height-enhancement treatment. Increlex mecasermin